CIO Bulletin
| Company | Management | Description |
|---|---|---|
| Biotecnol Limited | Pedro de Noronha Pissarra Ph.D CEO |
Biotecnol is a private biopharmaceutical company working in the field of immuno-oncology. Biotecnol develops highly-specific antibody-based immunotherapies which activates and directs the defences of a patient's own immune system, such as their own Killer T-Cells to fight various types of cancers where standard of care treatments have shown little or no benefit. |
|
|
David Main
|
Notch Therapeutics is developing a pipeline of cellular immunotherapies originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems. |
| Lumen Bioscience | Brian Finrow Co-Founder & CEO |
Lumen’s patented biologic drug platform shortens the development process, reduces costs and risks, and accelerates time-to-market, making us the first company to make orally delivered antibody drugs commercially viable. |
| Deep Genomics |
Brendan Frey Ph.D Founder & CEO |
The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Deep Genomics' geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using its biologically accurate artificial intelligence technology. |
| Accutar Biotech | Jie Fan PhD Founder & CEO |
AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. |
.webp)
 consultants ltd.jpg)
